Plasmapheresis to remove amyloid fibrin(ogen) particles for treating the post-COVID-19 condition.

Fox, Tilly; Hunt, Beverley J; Ariens, Robert As; Towers, Greg J; Lever, Robert; Garner, Paul; Kuehn, Rebecca

Fox, Tilly; Hunt, Beverley J; Ariens, Robert As; Towers, Greg J; Lever, Robert; Garner, Paul; Kuehn, Rebecca.

Afiliación

Fox T; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
Hunt BJ; King's Healthcare Partners, London, UK.
Ariens RA; Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
Towers GJ; Division of Infection and Immunity, University College London, London, UK.
Lever R; Imperial College London NHS Trust, London, UK.
Garner P; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
Kuehn R; Extraordinary Professor in Epidemiology and Biostatistics, Stellenbosch University, Stellenbosch, South Africa.

Cochrane Database Syst Rev ; 7: CD015775, 2023 07 26.

Article en En | MEDLINE | ID: mdl-37491597

Asunto(s)

COVID-19; Humanos; Fibrina/uso terapéutico; Plasmaféresis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 4_TD Problema de salud: 4_pneumonia Asunto principal: COVID-19 Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Cochrane Database Syst Rev Asunto de la revista: PESQUISA EM SERVICOS DE SAUDE Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google